Axsome Therapeutics Liabilities 2024

Axsome Therapeutics Aktienanalyse

What does Axsome Therapeutics do?

Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of severe psychiatric and neurological disorders. The company was founded in 2012 and is headquartered in New York City. The history of Axsome Therapeutics began with the identification of a new molecule called AXS-05, which was developed as a potential antidepressant and treatment for Alzheimer's disease. The company utilized its proprietary technology platform to optimize the drug's properties and then began conducting clinical studies to evaluate the efficacy and safety of AXS-05 in patients with depression, Alzheimer's disease, and other neurological disorders. Axsome Therapeutics' business model is based on the identification and development of novel drug candidates through the use of knowledge about novel target molecules and innovative technologies. The company aims to rapidly and cost-effectively develop its drugs to quickly achieve commercial benefits from its developments. The company relies on collaboration with strategic partners and acquisitions for faster market entry. Axsome Therapeutics is divided into several business areas, each identifying and developing different drug candidates. For example, one area is the field of pain medicine, where the company is developing novel therapies for chronic pain and migraines. Another area is psychiatric disorders, where the company focuses on novel treatments for depression, anxiety disorders, bipolar disorder, and post-traumatic stress disorder. A third area is neurodegenerative diseases, where the company is researching new approaches to treating Alzheimer's disease and Parkinson's disease. Axsome Therapeutics has several products in the pipeline at various stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III clinical trials for the treatment of depression and Alzheimer's disease. AXS-05 has been deemed safe and well-tolerated in previous studies and has shown significant improvement in symptoms in patients with severe depression. In studies on Alzheimer's and dementia, the medication showed preliminary improvement in specific disease symptoms. In addition to AXS-05, the company is also working on the development of AXS-12, a drug for the treatment of narcolepsy, and AXS-09, a combination of two known drugs for the treatment of migraines. In summary, Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development of novel therapies for the treatment of severe psychiatric and neurological disorders. The company has developed a proprietary technology platform that allows for cost-effective optimization and rapid development of drug candidates. Axsome Therapeutics is divided into several business areas and has several products in the pipeline at different stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III trials for the treatment of depression and Alzheimer's disease. Axsome Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Axsome Therapeutics's Liabilities

Axsome Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Axsome Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Axsome Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Axsome Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Axsome Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Axsome Therapeutics Stock

What is the level of liabilities of Axsome Therapeutics this year?

Axsome Therapeutics has a debt balance of 397.26 M USD this year.

What were the liabilities of Axsome Therapeutics compared to the previous year?

The liabilities of Axsome Therapeutics have increased by 79.03% increased compared to the previous year.

What are the consequences of high debt for investors of Axsome Therapeutics?

High liabilities can pose a risk for investors of Axsome Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Axsome Therapeutics?

Low liabilities mean that Axsome Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Axsome Therapeutics affect the company?

An increase in liabilities of Axsome Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Axsome Therapeutics affect the company?

A decrease in the liabilities of Axsome Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Axsome Therapeutics?

Some factors that can influence the liabilities of Axsome Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Axsome Therapeutics so important for investors?

The liabilities of Axsome Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Axsome Therapeutics take to modify the liabilities?

To change its liabilities, Axsome Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Axsome Therapeutics pay?

Over the past 12 months, Axsome Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Axsome Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Axsome Therapeutics?

The current dividend yield of Axsome Therapeutics is .

When does Axsome Therapeutics pay dividends?

Axsome Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Axsome Therapeutics?

Axsome Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Axsome Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Axsome Therapeutics located?

Axsome Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Axsome Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Axsome Therapeutics from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Axsome Therapeutics pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of Axsome Therapeutics in the year 2023?

In the year 2023, Axsome Therapeutics distributed 0 USD as dividends.

In which currency does Axsome Therapeutics pay out the dividend?

The dividends of Axsome Therapeutics are distributed in USD.